Core Viewpoint - The article highlights the significant growth and international expansion of China's pharmaceutical industry, emphasizing the government's support and the increasing number of Chinese pharmaceutical companies venturing abroad to enhance their competitiveness in the global market [3][4]. Industry Overview - China's pharmaceutical industry ranks second globally, with approximately 30% of innovative drugs under research worldwide. In 2025, 76 innovative drugs were approved for market, surpassing the 48 approved in 2024, marking a historical high [6]. - The total import and export value of China's pharmaceutical and medical device products reached $201.7 billion in 2025, reflecting a year-on-year growth of 1.18% [7]. Investment Trends - A survey indicated that 75% of responding pharmaceutical companies plan to maintain or expand their foreign investments, showcasing their determination and confidence in participating in international competition [8]. - The export of chemical preparations, such as penicillin and cephalosporins, saw growth rates of 26% and 6.7% respectively in 2025, with biological preparations in countries like Jordan, the Philippines, and Pakistan growing at an annual rate of 20% [8]. Government Support and Policies - The Chinese government has introduced several national-level initiatives to support the pharmaceutical industry's international expansion, including the establishment of regional platforms and a drug price registration system to enhance global pricing authority [10][11]. - New regulations effective from January 1, 2026, aim to facilitate exports by allowing GMP-compliant drugs to apply for export certificates regardless of their approval status in China, and extending the validity of export certificates from 2 to 3 years [12][13]. Infrastructure Development - Four major procurement platforms have been established to support pharmaceutical companies in their international endeavors, facilitating transactions and cross-border settlements [14]. - The China (Xinjiang) - Central Asia (Center) Pharmacy has already helped domestic pharmaceutical companies achieve export sales of 4.391 billion yuan [14].

Core Viewpoint - The company Chuaning Biological has reported significant growth in revenue and net profit, driven by increased sales and prices of its main products, as well as improvements in manufacturing processes through AI technology [1][2][3] Financial Performance - In 2024, Chuaning Biological achieved a revenue of 5.758 billion yuan, a year-on-year increase of 19.38%, and a net profit of 1.4 billion yuan, up 48.88%, both reaching historical highs [1] - The company's revenue from pharmaceutical intermediates was 5.356 billion yuan, an increase of over 900 million yuan from the previous year, with a year-on-year growth rate exceeding 20% [1] - The gross profit margin for the pharmaceutical intermediates business improved by 5.42 percentage points to 38.63% [1] Product and Market Insights - Chuaning Biological specializes in the research and sales of antibiotic intermediates, including three main categories: thiocyanate erythromycin, cephalosporin intermediates, and penicillin derivatives [1] - The revenue contribution from the three main products to total revenue was 32.35%, 24.96%, and 41.95%, respectively [1] AI and Technological Advancements - The company has begun utilizing AI to enhance manufacturing processes, achieving dynamic control in the production line of thiocyanate erythromycin, which has led to increased fermentation yields and reduced production fluctuations [2] - Chuaning Biological plans to continue leveraging AI and synthetic biology technologies to further stabilize production fluctuations and improve extraction yields by 2025 [3] Strategic Investments - In February of the previous year, Chuaning Biological acquired a 16.67% stake in Shanghai Jinchang Technology, which focuses on AI applications in biotechnology [2]